|
|
 |
I live in London augmentin flagyl diverticulitis The maker of aesthetic medicines said on Monday its ATX-101experimental injectable drug met the main and secondary goals ofa clinical study testing the product's safety and efficacy inreducing double chin. Over 1,000 patients from the United Statesand Canada were enrolled in two late-stage studies forevaluating the drug against a placebo, Kythera said.
2021-4-26 0:58:30 |
|
|
|
